Table of Contents
ISRN Oncology
Volume 2011, Article ID 936893, 5 pages
http://dx.doi.org/10.5402/2011/936893
Review Article

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer

1Department of Surgical Oncology, Gifu University Graduate School of Medicine, Yanagido, 1-1 Yanagido, Gifu 501-1194, Japan
2Department of Surgery, Ibi Welfare Hospital, Ibi, Gifu 501-0619, Japan

Received 16 February 2011; Accepted 8 April 2011

Academic Editor: A. R. Mackay

Copyright © 2011 Shuji Komori et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics,” Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. J. Chua and D. Cunningham, “Adjuvant treatment for resectable pancreatic cancer,” Journal of Clinical Oncology, vol. 23, no. 20, pp. 4532–4537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Oettle, S. Post, P. Neuhaus et al., “Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial,” Journal of the American Medical Association, vol. 297, no. 3, pp. 267–277, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. J. Moore, D. Goldstein, J. Hamm et al., “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1960–1966, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. H. A. Burris, M. J. Moore, J. Andersen et al., “Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2403–2413, 1997. View at Google Scholar · View at Scopus
  6. C. Louvet, R. Labianca, P. Hammel et al., “Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3509–3516, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Osada and S. Saji, “New approach to cancer therapy: the application of signal transduction to anti-cancer drug,” Current Medicinal Chemistry, vol. 3, no. 2, pp. 119–131, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Osada and B. I. Carr, “Critical role of extracellular signal-regulated kinase (ERK) phosphorylation in novel vitamin K analog-induced cell death,” Japanese Journal of Cancer Research, vol. 91, no. 12, pp. 1250–1257, 2000. View at Google Scholar · View at Scopus
  9. S. Osada, K. Osada, and B. I. Carr, “Tumor cell growth inhibition and extracellular signal-regulated kinase (ERK) phosphorylation by novel K vitamins,” Journal of Molecular Biology, vol. 314, no. 4, pp. 765–772, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Osada, H. Tomita, Y. Tanaka et al., “The utility of vitamin K3 (menadione) against pancreatic cancer,” Anticancer Research, vol. 28, no. 1A, pp. 45–50, 2008. View at Google Scholar · View at Scopus
  11. E. Mini, S. Nobili, B. Caciagli, I. Landini, and T. Mazzei, “Cellular pharmacology of gemcitabine,” Annals of Oncology, vol. 17, no. 5, pp. v7–v12, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. R. Mackey, R. S. Mani, M. Selner et al., “Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines,” Cancer Research, vol. 58, no. 19, pp. 4349–4357, 1998. View at Google Scholar · View at Scopus
  13. V. L. Damaraju, S. Damaraju, J. D. Young et al., “Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy,” Oncogene, vol. 22, no. 47, pp. 7524–7536, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Spratlin, R. Sangha, D. Glubrecht et al., “The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma,” Clinical Cancer Research, vol. 10, no. 20, pp. 6956–6961, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi, “Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer,” Molecular Cancer Therapeutics, vol. 5, no. 6, pp. 1387–1395, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. J. R. Kroep, W. J. Loves, C. L. van der Wilt et al., “Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity,” Molecular Cancer Therapeutics, vol. 1, no. 6, pp. 371–376, 2002. View at Google Scholar · View at Scopus
  17. A. M. Bergman, H. M. Pinedo, and G. J. Peters, “Determinants of resistance to 2,2-difluorodeoxycytidine (gemcitabine),” Drug Resistance Updates, vol. 5, no. 1, pp. 19–33, 2002. View at Google Scholar
  18. C. L. Van der Wilt, J. R. Kroep, A. M. Bergman et al., “The role of deoxycytidine kinase in gemcitabine cytotoxicity,” Advances in Experimental Medicine and Biology, vol. 486, pp. 287–290, 2000. View at Google Scholar · View at Scopus
  19. B. S. Zhou, P. Tsai, R. Ker et al., “Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential,” Clinical and Experimental Metastasis, vol. 16, no. 1, pp. 43–49, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Fan, C. Villegas, and J. A. Wright, “Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 24, pp. 14036–14040, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Nakano, S. Tanno, K. Koizumi et al., “Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells,” British Journal of Cancer, vol. 96, no. 3, pp. 457–463, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Ueno, K. Kiyosawa, and N. Kaniwa, “Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?” British Journal of Cancer, vol. 97, no. 2, pp. 145–151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Bepler, I. Kusmartseva, S. Sharma et al., “RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4731–4737, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. C. M. Ulrich, J. Bigler, R. Bostick, L. Fosdick, and J. D. Potter, “Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas,” Cancer Research, vol. 62, no. 12, pp. 3361–3364, 2002. View at Google Scholar · View at Scopus
  25. V. Garcia, J. M. García, C. Peña et al., “Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential,” Clinical Cancer Research, vol. 12, no. 7, part 1, pp. 2095–2100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. P. G. Johnston, J. C. Drake, J. Trepel, and C. J. Allegra, “Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines,” Cancer Research, vol. 52, no. 16, pp. 4306–4312, 1992. View at Google Scholar · View at Scopus
  27. S. Copur, K. Aiba, J. C. Drake, C. J. Allegra, and E. Chu, “Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil,” Biochemical Pharmacology, vol. 49, no. 10, pp. 1419–1426, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Ciaparrone, M. Quirino, G. Schinzari et al., “Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil,” Oncology, vol. 70, no. 5, pp. 366–377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Kamoshida, H. Matsuoka, T. Ishikawa et al., “Immunohistochemical evaluation of thymidylate synthase (TS) and p16 in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy,” Japanese Journal of Clinical Oncology, vol. 34, no. 10, pp. 594–601, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Takamura, Y. Nio, K. Yamasawa, M. Dong, K. Yamaguchi, and M. Itakura, “Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives,” Anti-Cancer Drugs, vol. 13, no. 1, pp. 75–85, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. C. Hu, R. A. Komorowski, S. Graewin et al., “Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer,” Clinical Cancer Research, vol. 9, no. 11, pp. 4165–4171, 2003. View at Google Scholar · View at Scopus
  32. D. R. Rauchwerger, P. S. Firby, D. W. Hedley, and M. J. Moore, “Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity,” Cancer Research, vol. 60, no. 21, pp. 6075–6079, 2000. View at Google Scholar · View at Scopus
  33. S. Komori, S. Osada, R. Mori et al., “Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer,” Pancreas, vol. 39, no. 8, pp. 1284–1292, 2010. View at Google Scholar
  34. S. Réjiba, C. Bigand, C. Parmentier, and A. Hajri, “Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies,” Neoplasia, vol. 11, no. 7, pp. 637–650, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Giovannetti, V. Mey, S. Nannizzi et al., “Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells,” Molecular Pharmacology, vol. 68, no. 1, pp. 110–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Y. Merl, O. Abdelghany, J. Li, and M. W. Saif, “First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the “2010 ASCO Annual Meeting”. Chicago, IL, USA. June 4–8, 2010,” Journal of the Pancreas, vol. 11, no. 4, pp. 317–320, 2010. View at Google Scholar